Biofrontera Earnings Call: Profits Rise, Risks Remain

Biofrontera, Inc. ((BFRI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Biofrontera, Inc. struck an upbeat tone on its latest earnings call, highlighting record sales, sharply improved gross margins, and a profitable fourth quarter as validation of its revamped U.S. business model. Management balanced this optimism with caution on ongoing cash burn, legal costs, and regulatory risk, but framed 2026 as the year when its strategic overhaul fully shows through in the numbers.

Record Revenue Performance

Biofrontera reported record full-year revenue of $41.7 million, up about 12% year over year, underscoring accelerating demand for Ameluz and its photodynamic therapy platform. Fourth-quarter revenue surged 36% to $17.1 million, marking the highest quarterly revenue in the company’s history and signaling strong momentum exiting 2025.

Quarterly Profitability and Margin Expansion

The company delivered a notably strong Q4, with adjusted EBITDA of $4.9 million and net income of $5.6 million, reversing a net loss in the prior-year quarter. Adjusted EBITDA margin swung from negative 11% a year ago to a healthy 29% in Q4 2025, demonstrating the operating leverage inherent in the new cost structure.

Gross Profit Gains from Strategic Transaction

A key driver of profitability was the steep decline in related-party cost of goods sold following the new transaction with its former parent, which cut Q4 COGS by roughly 45% year over year. As a result, gross profit on product sales climbed from about 50% to 74% for full-year 2025, with Q4 gross margin reaching roughly 82%, transforming Biofrontera’s unit economics.

Acquisition of U.S. Commercial and Regulatory Assets

Management emphasized the strategic importance of acquiring the U.S. rights, regulatory filings, manufacturing, and patents from Biofrontera AG, which gives the company full control over the U.S. Ameluz franchise. The prior 25–35% transfer-pricing arrangement has been replaced by a 12–15% earn-out, materially lowering long-term COGS and supporting sustainable margin expansion.

Commercial Execution and Volume Growth

On the commercial front, Ameluz unit volumes climbed to roughly 121,000 tubes for the year, implying about 10% growth, with Q4 shipments near 49,840 tubes as utilization increased. The installed base of RhodoLED lamps reached about 745 across roughly 686 dermatology offices, including around 85 new placements in 2025, which supports recurring treatment-driven revenue.

Clinical and Regulatory Milestones

Clinically, Biofrontera reported strong Phase III data in superficial basal cell carcinoma, where Ameluz showed 76% complete histological clearance versus 19% for placebo and a similarly impressive clinical clearance gap, underpinning a supplemental filing with a set review timeline. The company also reported a successful Phase III trial for actinic keratoses on extremities and positive Phase II acne data, pointing to a broader label and longer-term growth optionality.

Strengthened IP Position and Legal Outcomes

The firm secured approval for an improved Ameluz formulation that removes propylene glycol, extending patent life through December 2043 and potentially enhancing product differentiation. In parallel, a U.S. patent board ruled that challenged claims of a rival’s patent were unpatentable, which management views as a favorable step in ongoing intellectual property disputes, even as further legal review remains possible.

Liquidity and Recent Financing Actions

To bolster its balance sheet, Biofrontera raised $11 million in gross proceeds via a Series C preferred private placement and received an initial $3 million from the sale of Xepi license rights. These transactions helped lift strategic flexibility, but cash and equivalents still stood at a modest $6.4 million at year-end, underscoring the importance of continued careful cash management.

Full-Year Losses and Negative Adjusted EBITDA

Despite the profitable fourth quarter, Biofrontera posted a full-year operating loss of $11.3 million and a GAAP net loss of $10.5 million, though both metrics showed solid improvement versus 2024. Adjusted EBITDA for the year remained negative at $10.6 million, equating to a margin of minus 25.4%, highlighting the gap that still must be closed to achieve consistent profitability.

Cash Burn and Limited Liquidity Headroom

Cash used in operating activities totaled $13.4 million for 2025, signaling ongoing cash consumption as the company invests in sales growth and clinical development. With only $6.4 million of cash on hand at year-end, even after financing actions, investors are likely to focus on the pace of burn and the timing of reaching cash-flow breakeven.

Elevated Legal Expenses and SG&A Pressures

Selling, general and administrative expenses increased about 12% to $38.4 million, driven mainly by a $6 million rise in legal costs tied to patent-related litigation. While management argued that defending and strengthening the IP position is critical for long-term value, these legal expenses weigh on near-term profitability and add uncertainty around future spending levels.

Transition and Earn-Out Costs in 2025

The company cautioned that 2025 results only partially reflect the benefit of the new 12% earn-out structure, as about 45% of Ameluz sales were still under legacy terms. Roughly $2.2 million in earn-out payments and one-time transition items constrained the full-year margin upside, but management expects a significantly cleaner and more favorable cost profile from 2026 onward.

Higher R&D Spend and Clinical Investment

Research and development expenses rose $1.6 million to $3.7 million as Biofrontera assumed responsibility for U.S. clinical programs that its former parent previously funded. Management framed this step-up as necessary to advance Phase III and registrational work across sBCC, AK extremities, and acne, though it amplifies short-term funding needs and execution demands.

Regulatory Dependence and Binary Risk

The company’s medium-term growth story rests heavily on upcoming regulatory decisions, including supplemental applications for sBCC, broader AK use, and potential acne indications. Any delay or negative outcome could materially affect revenue upside and valuation, making these binary events key watchpoints for shareholders over the next couple of years.

Guidance and Outlook

Looking ahead, management guided that the full annualized benefit of the new earn-out structure should be realized in 2026, with gross margins expected in the 80–85% range as cost of revenue per unit falls to around 15%. The company aims to reduce cash consumption on the path to cash-flow breakeven, leveraging 2025’s $41.7 million in revenue, strong Q4 profitability, and incremental financing to fund its commercial push and late-stage pipeline.

Biofrontera’s latest call painted a picture of a company turning an inflection point, with record sales, structurally higher margins, and a clear path to expanding its dermatology franchise. Yet full-year losses, finite liquidity, heavy legal spending, and reliance on successful FDA outcomes mean investors must weigh meaningful upside potential against continued execution and regulatory risk.